Clinical Trials Sponsored by Novartis Pharmaceuticals

Total 21474 results

Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Pharmaceutical Research Associates

Withdrawn

Pharmacokinetics Study of TNO155 in Participants With Mild, Moderate, or Severe Renal Impairment Compared to Matched Healthy Participants

Renal Impairment
Novartis Pharmaceuticals
Pharmaceutical Research Associates

Withdrawn

Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants

Hepatic Impairment
Novartis Pharmaceuticals
Ono Pharmaceutical Co. Ltd

Completed

Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)

Alzheimer's Disease

Japan
Novartis Pharmaceuticals
Ono Pharmaceutical Co. Ltd

Completed

Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

Japan
Novartis Pharmaceuticals
Ono Pharmaceutical Co. Ltd

Completed

Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors

Alzheimer's Disease

Japan
Novartis Pharmaceuticals

Not yet recruiting

A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.

Hypercholesterolemia
Novartis Pharmaceuticals

Not yet recruiting

Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation (ASC4INDIA)

Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
Novartis Pharmaceuticals

Not yet recruiting

Iptacopan in Patients With ANCA Associated Vasculitis

Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
Novartis Pharmaceuticals

Not yet recruiting

ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients

Multiple Sclerosis, Relapsing-Remitting
Novartis Pharmaceuticals

Not yet recruiting

Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

Rheumatoid Arthritis | Systemic Lupus Erythematosus | Sjögrens Disease
Novartis Pharmaceuticals

Not yet recruiting

Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD

Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals

Recruiting

A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical Practice (CRONOS-MS)

Relapsing Forms of Multiple Sclerosis

Spain
Novartis Pharmaceuticals

Recruiting

Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy

Hypertension

Japan
Novartis Pharmaceuticals

Not yet recruiting

Kesimpta Pregnancy and Infant Safety Study Using Real World Data

Multiple Sclerosis
Novartis Pharmaceuticals

Recruiting

Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France (SEPROS)

Multiple Sclerosis (MS)

France
Novartis Pharmaceuticals

Recruiting

Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)

Sickle Cell Disease

United States
Novartis Pharmaceuticals

Recruiting

A Prospective NIS to Evaluate the Clinical Outcomes of Risarg® (Ribociclib) Combined With Endocrine Therapy or Chemotherapy in Patients With HR+HER2 - aBC in Routine Clinical Practice in the Russia (ValerEE)

HR+HER2- Advanced Breast Cancer

Russian Federation
Novartis Pharmaceuticals

Recruiting

A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)

Coronary Heart Disease | Clonal Hematopoiesis of Indeterminate Potential (CHIP)

Germany, Canada, United States
Novartis Pharmaceuticals

Recruiting

A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease

Coronary Heart Disease

United States
Novartis Pharmaceuticals

Recruiting

A Randomized, Double-blind 2-arm NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome. (NEPTUNUS-Ext)

Sjogrens Syndrome

Japan, United States, Spain, Austria, Belgium, Germany, Turkey, Hungary, Israel, Taiwan, Italy, France, Colombia, Argentina, Portugal, Australia, Slovakia, United Kingdom, Guatemala, Brazil, Czechia, Poland, Bulgaria, Canada, Lithuania, R...
Novartis Pharmaceuticals

Recruiting

A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.

Glioblastoma Multiforme | Gastroesophageal Adenocarcinoma | Pancreatic Ductal Adenocarcinoma

Netherlands, Spain, Israel, United States, Switzerland
Novartis Pharmaceuticals

Recruiting

A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

Chronic Inducible Urticaria

China, United States, Australia, Korea, Republic of, Israel, Turkey, Hong Kong, Japan, Malaysia, Singapore, Argentina, Thailand, Canada
Novartis Pharmaceuticals

Recruiting

Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

Atypical Hemolytic Uremic Syndrome

Japan, Turkey
Novartis Pharmaceuticals

Recruiting

Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa. (ANIMA)

Hidradenitis Suppurativa

Germany
Novartis Pharmaceuticals

Recruiting

Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors (HU-F-AIM)

Polycythemia Vera

Germany
Novartis Pharmaceuticals

Recruiting

A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC (PSMACare)

Prostatic Neoplasm

Korea, Republic of, Singapore, United States, Canada, Poland, Spain, Czechia
Novartis Pharmaceuticals

Recruiting

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

Prostate Cancer

United States
Novartis Pharmaceuticals

Recruiting

An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus

Systemic Lupus Erythematosus | Lupus Nephritis

Spain, Switzerland, Germany, Australia, France, United States
Novartis Pharmaceuticals

Not yet recruiting

Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS

Atypical Hemolytic Uremic Syndrome
Novartis Pharmaceuticals

Recruiting

Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years (KRONOS)

Relapsing Multiple Sclerosis

Austria
Novartis Pharmaceuticals

Recruiting

Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma

Newly Diagnosed and Recurrent Glioblastoma

Spain, Israel, Portugal
Novartis Pharmaceuticals

Recruiting

The Belgian REAL (BE.REAL) Registry (BE REAL)

Atherosclerotic Cardiovascular Disease

Belgium
Novartis Pharmaceuticals

Recruiting

A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

Non-Small-Cell Lung Carcinoma

Korea, Republic of
Novartis Pharmaceuticals

Recruiting

Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France (RosaLEE)

Breast Cancer

France
Novartis Pharmaceuticals

Recruiting

Long-term Extension Study of Ligelizumab in Food Allergy

Food Allergy

Spain, France, Germany, Italy, United States, Netherlands, Canada, Japan, Australia
Novartis Pharmaceuticals

Recruiting

Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PROUD)

Macular Polypoidal Choroidal Vasculopathy (PCV)

Korea, Republic of
Novartis Pharmaceuticals

Recruiting

Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment (ALPINIST)

Advanced Breast Cancer

India
Novartis Pharmaceuticals

Recruiting

Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) (SIRIUS-SLE 2)

Systemic Lupus Erythematosus

United States, Germany, France, Taiwan, Italy, India, Argentina, Korea, Republic of, Mexico, Malaysia, Chile, Colombia, Romania, Australia, United Kingdom
Novartis Pharmaceuticals

Recruiting

A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission

Non-radiographic Axial Spondyloarthritis

Belgium, Netherlands, Italy, Thailand, Hungary, Malaysia, Germany, Israel, France, Czechia, Colombia, Romania, Poland, Turkey, Vietnam, Brazil, Mexico, Philippines
Novartis Pharmaceuticals

Recruiting

Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera (Prospero)

Polycythemia Vera

Italy
Novartis Pharmaceuticals

Recruiting

A Proof-of-concept Study to Examine QUC398 in Participants With Knee OA

Osteoarthritis, Knee

Spain, United States, Denmark, France, Australia, Norway
Novartis Pharmaceuticals

Recruiting

A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas

Metastatic Uveal Melanoma

United States, Australia, France, Netherlands, Switzerland, Germany, Spain
Novartis Pharmaceuticals

Recruiting

Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia (ASC2ESCALATE)

Chronic Myelogenous Leukemia - Chronic Phase

United States
Novartis Pharmaceuticals

Recruiting

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (KontRASt-03)

Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Colorectal Cancer | Non-Small Cell Lung Cancer | Nonsmall Cell Lung Cancer | Carcinoma, Non-Small Cell Lung | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, Colorectal | Non-Small Cell Lung Carcinoma | KRAS G12C Mutant Solid Tumors

Korea, Republic of, Spain, Belgium, United States, France, Germany, Italy, Singapore
Novartis Pharmaceuticals

Recruiting

Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome (NEPTUNUS-1)

Sjogren Syndrome

Brazil, Portugal, United States, Belgium, Spain, Chile, Germany, Korea, Republic of, Guatemala, Czechia, Mexico, France, Turkey, China, Austria, Poland, Singapore, Lithuania
Novartis Pharmaceuticals

Recruiting

A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.

Small Cell Lung Carcinoma

United States
Novartis Pharmaceuticals

Recruiting

Regulatory PMS Study for Lucentis® in Patients With Retinopathy of Prematurity

Retinopathy of Prematurity

Korea, Republic of

3

Subscribe